Developer docs
API playgroundTry for free, no card

Search company profiles

SpIntellx

Full company profile

uuid00037ai

Namestring
SpIntellx
Legal namestring
PredxBio, Inc.
Websiteurl
spintellx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SpIntellx, operating commercially as PredxBio, Inc., is a Pittsburgh-based spatial tissue intelligence company founded in 2017 that builds decision-support software for pharmaceutical and biotechnology drug development teams. Its core product, the SpaceIQ platform, ingests complex spatial multi-omic tissue data — including functional cell states, spatial microenvironments, and cell-cell interactions — and applies machine learning, image processing, and computational biology algorithms to surface response-defining tissue patterns. The platform is structured around three interconnected modules: Discovery & Mechanism Intelligence (target and mechanism-of-action support), Translational & Clinical Readiness (biomarker and patient stratification), and Trial & Program-Scale Decision Support (trial design, inclusion criteria refinement, go/no-go decisions).

The company is led by CEO B. Dusty Majumdar, PhD (formerly of GE Healthcare, Exact Sciences, and 3M), Sr. VP Business Development Joe Camaratta (former GE Healthcare and Siemens Healthcare executive), and VP Software Engineering Bruce Campbell, MS (former IBM Global Director of Data Science with 20+ years shipping FDA 510(k)-cleared and CLIA-certified digital pathology algorithms). IP basis includes multiple filed patents held by Dr. Majumdar.

Commercial motion is enterprise field sales targeting pharma and biotech R&D decision-makers, supported by content marketing (whitepapers, newsletter), direct engagement CTAs, and an event-led demand generation layer anchored by the proprietary Spatial Intelligence Summit (Pittsburgh, annually) and major conference presence (AACR 2026: six posters, Booth #1723). Revenue mechanics appear to be enterprise subscription or platform licensing with quote-based pricing, though commercial terms are not publicly disclosed. Cumulative disclosed funding is approximately $1.67M across nine rounds (2018-2023) from Innovation Works, Keiretsu Capital, AlphaLab Health, Newlin Investment Company, and a National Science Foundation SBIR award, supporting a small 1-10 person team operating from 100 S Jackson Avenue, Pittsburgh, PA.

Short descriptiontext

SpIntellx (operating as PredxBio) is a Pittsburgh-based spatial tissue intelligence company whose SpaceIQ platform applies machine learning to spatial multi-omic data to support drug development decisions for pharmaceutical and biotechnology R&D teams.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial biology software, drug development analytics, digital pathology platform, tissue intelligence, multi-omic data analysis
Industry2 codes
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Development Analytics Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Software Platform/SaaS
TypeSubscription Recurring
Description

SpaceIQ platform appears to be offered as a software solution to pharmaceutical and biotech companies for tissue intelligence analysis. Revenue likely derives from platform licensing or subscription, though specific commercial terms are not disclosed.

predxbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1SpaceIQ
Description

Decision-intelligence platform that transforms complex tissue and multi-omic spatial data into trusted, explainable insights for drug development - from early discovery through clinical programs and portfolio strategy.

predxbio.com
Core offering1 text field

SpIntellx (operating through PredxBio, Inc.) develops and sells the SpaceIQ decision-intelligence platform, which transforms complex tissue and multi-omic spatial data into explainable insights for pharmaceutical and biotech drug development teams. The platform supports discovery and mechanism intelligence, translational and clinical biomarker development, and trial-scale decision support through machine learning, image processing, and computational biology algorithms.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

PredxBio offers a single unified platform called SpaceIQ™ that provides decision-grade tissue intelligence for drug development. The platform operates across three interconnected phases: Discovery & Mechanism Intelligence (reveals response-defining tissue biology to inform target selection and mechanism-of-action hypotheses), Translational & Clinical Readiness (defines predictive tissue-based biomarkers and patient stratification based on tissue-level biology linked to therapeutic response), and Trial & Program-Scale Decision Support (applies consistent, reproducible tissue intelligence across studies to guide trial strategy and enable learning to compound across programs). The platform processes spatial multi-omic data to uncover response-driving biology that conventional analyses miss.

Product and service1 record
1SpaceIQ Platform
CategoryDrug Development Analytics Software
Description

Decision-intelligence platform that transforms complex tissue and multi-omic spatial data into trusted, explainable insights that guide drug development — from early discovery through clinical programs and portfolio strategy. It is sold to pharmaceutical and biotech drug development teams and operates through three interconnected capabilities: Discovery & Mechanism Intelligence, Translational & Clinical Readiness, and Trial & Program-Scale Decision Support.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeGTM or Marketing Partner
Description

Joe Camaratta serves as an advisor to the Entrepreneurial Investing Program of the Crohn's & Colitis Foundation, indicating a minor advisory/marketing partnership relationship.

2University Science Center QED Program
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joe Camaratta serves as an advisor to the University Science Center QED Program focused on commercialization of academic innovations, indicating a minor strategic advisory relationship.

predxbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SpIntellx

Drug Development Analytics Softwarespintellx.com

SpIntellx (operating as PredxBio) is a Pittsburgh-based spatial tissue intelligence company whose SpaceIQ platform applies machine learning to spatial multi-omic data to support drug development decisions for pharmaceutical and biotechnology R&D teams.

What SpIntellx does

SpIntellx, operating commercially as PredxBio, Inc., is a Pittsburgh-based spatial tissue intelligence company founded in 2017 that builds decision-support software for pharmaceutical and biotechnology drug development teams. Its core product, the SpaceIQ platform, ingests complex spatial multi-omic tissue data — including functional cell states, spatial microenvironments, and cell-cell interactions — and applies machine learning, image processing, and computational biology algorithms to surface response-defining tissue patterns. The platform is structured around three interconnected modules: Discovery & Mechanism Intelligence (target and mechanism-of-action support), Translational & Clinical Readiness (biomarker and patient stratification), and Trial & Program-Scale Decision Support (trial design, inclusion criteria refinement, go/no-go decisions).

The company is led by CEO B. Dusty Majumdar, PhD (formerly of GE Healthcare, Exact Sciences, and 3M), Sr. VP Business Development Joe Camaratta (former GE Healthcare and Siemens Healthcare executive), and VP Software Engineering Bruce Campbell, MS (former IBM Global Director of Data Science with 20+ years shipping FDA 510(k)-cleared and CLIA-certified digital pathology algorithms). IP basis includes multiple filed patents held by Dr. Majumdar.

Commercial motion is enterprise field sales targeting pharma and biotech R&D decision-makers, supported by content marketing (whitepapers, newsletter), direct engagement CTAs, and an event-led demand generation layer anchored by the proprietary Spatial Intelligence Summit (Pittsburgh, annually) and major conference presence (AACR 2026: six posters, Booth #1723). Revenue mechanics appear to be enterprise subscription or platform licensing with quote-based pricing, though commercial terms are not publicly disclosed. Cumulative disclosed funding is approximately $1.67M across nine rounds (2018-2023) from Innovation Works, Keiretsu Capital, AlphaLab Health, Newlin Investment Company, and a National Science Foundation SBIR award, supporting a small 1-10 person team operating from 100 S Jackson Avenue, Pittsburgh, PA.

SpIntellx firmographics

Firmographics
Name
SpIntellx
Legal name
PredxBio, Inc.
Website
https://spintellx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
SpIntellx (operating as PredxBio) is a Pittsburgh-based spatial tissue intelligence company whose SpaceIQ platform applies machine learning to spatial multi-omic data to support drug development decisions for pharmaceutical and biotechnology R&D teams.
Ownership category
akta.pro rank

Where SpIntellx is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SpIntellx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Software Platform/SaaS: SpaceIQ platform appears to be offered as a software solution to pharmaceutical and biotech companies for tissue intelligence analysis. Revenue likely derives from platform licensing or subscription, though specific commercial terms are not disclosed.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

SpIntellx product offering

Product offering

Core offering

SpIntellx (operating through PredxBio, Inc.) develops and sells the SpaceIQ decision-intelligence platform, which transforms complex tissue and multi-omic spatial data into explainable insights for pharmaceutical and biotech drug development teams. The platform supports discovery and mechanism intelligence, translational and clinical biomarker development, and trial-scale decision support through machine learning, image processing, and computational biology algorithms.

Product overview

PredxBio offers a single unified platform called SpaceIQ™ that provides decision-grade tissue intelligence for drug development. The platform operates across three interconnected phases: Discovery & Mechanism Intelligence (reveals response-defining tissue biology to inform target selection and mechanism-of-action hypotheses), Translational & Clinical Readiness (defines predictive tissue-based biomarkers and patient stratification based on tissue-level biology linked to therapeutic response), and Trial & Program-Scale Decision Support (applies consistent, reproducible tissue intelligence across studies to guide trial strategy and enable learning to compound across programs). The platform processes spatial multi-omic data to uncover response-driving biology that conventional analyses miss.

Differentiator

Problem solved

Functional benefit

Brands

  • SpaceIQ: Decision-intelligence platform that transforms complex tissue and multi-omic spatial data into trusted, explainable insights for drug development - from early discovery through clinical programs and portfolio strategy.

Products and services

  • SpaceIQ Platform Decision-intelligence platform that transforms complex tissue and multi-omic spatial data into trusted, explainable insights that guide drug development — from early discovery through clinical programs and portfolio strategy. It is sold to pharmaceutical and biotech drug development teams and operates through three interconnected capabilities: Discovery & Mechanism Intelligence, Translational & Clinical Readiness, and Trial & Program-Scale Decision Support.

Companies that use SpIntellx

Customer profile

Segments1 record

Ideal customer profiles1 record

SpIntellx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

SpIntellx partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Crohn's & Colitis FoundationminorGTM or Marketing PartnerJoe Camaratta serves as an advisor to the Entrepreneurial Investing Program of the Crohn's & Colitis Foundation, indicating a minor advisory/marketing partnership relationship.
  • University Science Center QED ProgramminorStrategic or Co-development PartnerJoe Camaratta serves as an advisor to the University Science Center QED Program focused on commercialization of academic innovations, indicating a minor strategic advisory relationship.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

SpIntellx competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat4 records

Customer concentration

SpIntellx social profiles

Digital presence

SpIntellx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SpIntellx leadership team

Management profile

Number of profiles

Profiles3 records

SpIntellx funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SpIntellx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpIntellx

What does SpIntellx do?

SpIntellx (operating through PredxBio, Inc.) develops and sells the SpaceIQ decision-intelligence platform, which transforms complex tissue and multi-omic spatial data into explainable insights for pharmaceutical and biotech drug development teams. The platform supports discovery and mechanism intelligence, translational and clinical biomarker development, and trial-scale decision support through machine learning, image processing, and computational biology algorithms.

Is SpIntellx a public or private company?

SpIntellx is a private company. It is classified as venture growth investor backed and is currently operating.

When was SpIntellx founded?

SpIntellx was founded in 2017. It employs 11 to 50 people.

Where is SpIntellx based?

SpIntellx is headquartered in Pittsburgh, United States, in the North America region.

How does SpIntellx make money?

One revenue line is on record: software Platform/SaaS.

Does SpIntellx have an API?

No public API is recorded for SpIntellx.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales